Mount Sinai Institutes for Clinical and Translational Sciences
西奈山临床和转化科学研究所
基本信息
- 批准号:7878933
- 负责人:
- 金额:$ 33.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-14 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:CaregiversClinicalClinical InvestigatorClinical ResearchClinical TrialsClinical Trials DesignCollaborationsCommunitiesConsultationsCountryDevelopmentEnvironmentFosteringFutureGeneral PopulationGoalsGrantHealth BenefitHealth ProfessionalHome environmentHospitalsInformation NetworksInstitutesInstitutionInstructionLaboratoriesMentorsMethodologyParticipantPatientsProceduresRecruitment ActivityResearchResearch InfrastructureResearch InstituteResearch PersonnelResearch Project GrantsResourcesRewardsScienceScientific Advances and AccomplishmentsScientistStructureTechnologyTherapeuticTrainingTraining SupportTranslatingTranslational ResearchTranslationsbench to bedsidecareer developmentclinical practiceimprovedinterdisciplinary collaborationmedical schoolsmultidisciplinarynovelprogramsstandard of care
项目摘要
Despite great scientific advances over the past decade, the translation of these discoveries to the benefit of
patients has been hampered by a number of traditional barriers. The overall goal of the iWioyinit Siimai
ImstitiLiiites of ClBrnical & Tiramslatioinial Sciences is to establish a new research paradigm at Mount Sinai,
which will create an integrated multidisciplinary environment that will enable translation of cutting-edge
research more quickly and easily from "bench-to-bedside-to-implementation" in the community; train and
create an "academic home" for the clinical and translational investigators of tomorrow; and supply the
governance, facilities, resources and opportunities needed to elevate the clinical research enterprise so that
clinical investigators can take full advantage of Mount Sinai's Translational Research Institutes and potential
collaborators in Mount Sinai Hospital and its affiliates, the School of Medicine and partnering institutions, and
other CTSA programs around the country. This transformation will be achieved by fulfilling the following
Specific Aims: (1) redesign the institutional research enterprise infrastructure and governance by integrating
research functions across administrative, departmental and intellectual boundaries, enhancing and
promoting interactions between basic scientists and clinical investigators, and streamlining administrative
procedures to facilitate the start-up of clinical trials and the dissemination of results; (2) establish a
Translational Discoveries Program to facilitate and expedite clinical research by providing consultation,
oversight and facilities for clinical and translational research, engaging the surrounding community and our
affiliates to rapidly translate health benefits to the general population, and developing new methodologies to
improve clinical trial design and reduce participant burden; (3) train and support the translational
investigators of tomorrow by overseeing a multi-disciplinary, doctoral degree-granting program in clinical and
translational research for all health care professionals, developing a program to recruit, enhance career
development and retain clinical and translational researchers, providing an academic home where new
collaborations can be formulated; (4) establish an Experimental Therapeutics& Technologies Program to
stimulate the development of new methodologies in clinical and translational research by developing an
institution-wide mentored program to identify and develop novel clinical and translational research projects;
and (5) establish an institution-wide biomedical information infrastructure that can connect basic researchers,
clinical researchers, caregivers and laboratories with an integrated network of information.
RELEVANCE (See instructions):
The establishment of the ilfloynt Siinao Institutes of Clinical & Tiranslational Sciemces would create an
effective, efficient and centralized research administrative structure, foster and reward interdisciplinary
collaborations, educate and retain the clinical and translational investigators of the future, enable translation
of basic scientific discoveries into clinical practice, and deliver to our diverse community new therapies and a
standard of care that would have been unimaginable even five years ago.
尽管在过去的十年里,科学取得了巨大的进步,但这些发现的翻译对人类有益
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hugh A Sampson其他文献
Standardization of anti-asthma herbal formula MSSM-002 by HPLC chromatographic fingerprint
- DOI:
10.1016/s0091-6749(02)81886-3 - 发表时间:
2002-01-01 - 期刊:
- 影响因子:
- 作者:
Zhong-Mei Zou;Hugh A Sampson;Xiu-Min Li - 通讯作者:
Xiu-Min Li
The Chinese herbal formula, MSSM-002, can reverse the established Th2 phenotype, which is accompanied with down regulation of the th2 transcription factor GATA-3
- DOI:
10.1016/s0091-6749(02)81592-5 - 发表时间:
2002-01-01 - 期刊:
- 影响因子:
- 作者:
Xiu-Min Li;Ariel Teper;Zhong-Mei Zou;Kamal D Srivastava;Brian H Schofield;Hugh A Sampson - 通讯作者:
Hugh A Sampson
Detection of milk proteins in dry powder inhalers containing lactose
- DOI:
10.1016/s0091-6749(02)81924-8 - 发表时间:
2002-01-01 - 期刊:
- 影响因子:
- 作者:
Anna H Nowak-Wegrzyn;Ludmilla Bardina;Kirsten Beyer;Wayne G Shreffler;Hugh A Sampson - 通讯作者:
Hugh A Sampson
Effects of preparation methods on the allergenicity of peanut in a murine model of peanut-induced anaphylaxis
- DOI:
10.1016/s0091-6749(02)81676-1 - 发表时间:
2002-01-01 - 期刊:
- 影响因子:
- 作者:
Hayf Emeil Al-Mussawir;Kamal D Srivastava;Kirsten Beyer;Jin-Hua Li;Side Li;Wesley Burks;Gary A Bannon;Xiu-Min Li;Hugh A Sampson - 通讯作者:
Hugh A Sampson
Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study
重复肾上腺素给药时间以告知儿科过敏反应观察期:一项回顾性队列研究
- DOI:
10.1016/s2352-4642(25)00139-7 - 发表时间:
2025-07-01 - 期刊:
- 影响因子:15.500
- 作者:
Timothy E Dribin;Hugh A Sampson;Yin Zhang;Stephanie Boyd;Nanhua Zhang;Kenneth A Michelson;Mark I Neuman;David C Brousseau;Rakesh D Mistry;Stephen B Freedman;Paul L Aronson;Kelly R Bergmann;Brittany Boswell;Sri S Chinta;Wee-Jhong Chua;Ari R Cohen;Joanna S Cohen;Alicia Daggett;Justin R Davis;Julia F Freeman;Seth Woolf - 通讯作者:
Seth Woolf
Hugh A Sampson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hugh A Sampson', 18)}}的其他基金
MOUNT SINAI INSTITUTES FOR CLINICAL AND TRANSLATIONAL SCIENCES
西奈山临床和转化科学研究所
- 批准号:
8364989 - 财政年份:2011
- 资助金额:
$ 33.39万 - 项目类别:
Immunologic Responses to Cow's Milk Proteins in IgE-mediated Cow's Milk Allergy
IgE 介导的牛奶过敏中牛奶蛋白的免疫反应
- 批准号:
8034293 - 财政年份:2010
- 资助金额:
$ 33.39万 - 项目类别:
相似国自然基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Cancer Clinical Investigator Team Leadership Award
癌症临床研究者团队领导奖
- 批准号:
8759976 - 财政年份:2013
- 资助金额:
$ 33.39万 - 项目类别:
Clinical Investigator Training Enhancement Program--CITE
临床研究者培训强化计划
- 批准号:
7278287 - 财政年份:2000
- 资助金额:
$ 33.39万 - 项目类别:
Clinical Investigator Training Enhancement Program--CITE
临床研究者培训强化计划
- 批准号:
7122464 - 财政年份:2000
- 资助金额:
$ 33.39万 - 项目类别: